Scholarlink

Objective <p>This study aimed to evaluate the effect of LV in combination with gabapentin, a first-line medication for RLS, on the treatment of patients with the condition.</p> Results <p>In total, 36 participants (18 in each group) participated in this study, with 10 (55%) being male within each group. The mean age of participants was 45 years (SD = 10.6) in the LV group and 49.1 (SD = 8.3) in the gabapentin group. In both the LV and gabapentin groups, IRLSSG scores decreased significantly after the intervention compared with baseline (<i>p</i> &lt; 0.001). However, scores increased at the one-month follow-up, although they remained lower than pre-intervention values (<i>p</i> &lt; 0.001). A similar pattern was observed for the PSQI scores (<i>p</i> &lt; 0.001). There were no significant differences between groups at any timepoint (<i>p</i> &gt; 0.05).</p> Trial registration <p>The study protocol was registered at the Iranian Registry of Clinical Trials on August 30th, 2023 (code IRCT20190306042945N4).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of local vibration therapy and gabapentin on restless legs syndrome symptoms: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Gholamreza Raissi,
  • Bijan Forogh,
  • Hamid Ansari,
  • Seyed Pezhman Madani,
  • Masumeh Bagherzadeh Cham,
  • Hosna Soleymanzadeh

摘要

Objective

This study aimed to evaluate the effect of LV in combination with gabapentin, a first-line medication for RLS, on the treatment of patients with the condition.

Results

In total, 36 participants (18 in each group) participated in this study, with 10 (55%) being male within each group. The mean age of participants was 45 years (SD = 10.6) in the LV group and 49.1 (SD = 8.3) in the gabapentin group. In both the LV and gabapentin groups, IRLSSG scores decreased significantly after the intervention compared with baseline (p < 0.001). However, scores increased at the one-month follow-up, although they remained lower than pre-intervention values (p < 0.001). A similar pattern was observed for the PSQI scores (p < 0.001). There were no significant differences between groups at any timepoint (p > 0.05).

Trial registration

The study protocol was registered at the Iranian Registry of Clinical Trials on August 30th, 2023 (code IRCT20190306042945N4).